Introduction {#sec1-1}
============

Nerve cells, once damaged or degenerated, cannot self-repair. Can the loss of neural function caused by neurological disorders be clinically improved or even cured by nerve regeneration or functional replacement by adjacent nerves? Neurons and glial cells differentiated from stem cells from different sources have brought hope for this issue (Chao et al., 2018). The clinical application of endogenous neural stem cells (NSCs) has been restricted by their specialized location and limited quantities. The successful differentiation of exogenous stem cells from other tissues into neural cells has provided a new source of NSCs (Zhang et al., 2018). However, induced differentiation *in vitro* is influenced by many factors and how a suitable microenvironment that favors neuronal differentiation and provides effective nutritional factors to promote neuronal growth can be created *in vitro* remains a problem (Wei et al., 2015). Although there are many ways to induce stem cells *in vitro*, there is still no single way to accurately induce the differentiation of exogenous stem cells into neurons. Hence, it is a focus of current research to find a controllable induction method for stem cell differentiation into neurons, bringing hope to patients suffering neurological disorders.

At present, the main induction methods include: (1) Cell growth factor induction by epidermal growth factor, basic fibroblast growth factor and nerve growth factor (Low et al., 2010); (2) chemical induction by β-mercaptoethanol, dimethyl sulfoxide, and butylated hydroxyanisole (Kang et al., 2006); and (3) growth factor and chemical combined induction: Woodbury et al. (2001) used β-mercaptoethanol, dimethyl sulfoxide, and basic fibroblast growth factor combined induction, while Gesine et al. (2004) utilized nerve growth factor, basic fibroblast growth factor, dibutyryl cyclic AMP, isobutylmethyl xanthine and all-trans-retinoic acid for combined induction of bone marrow mesenchymal stem cells (MSCs) into nerve cells *in vitro*; (4) other methods (Ren et al., 2014) such as traumatic brain tissue homogenate, gene transfection, traditional Chinese medicine (Baicalin and Salvia miltiorrhiza), co-culture, and conditioned growth medium close to the physiological state.

Cytokines are currently commonly used inducers due to their extensive function in neural nutrition, anti-free radical activity, calcium overload reducing, and inhibition of nitric oxide synthase expression. Among them, epidermal growth factor and basic fibroblast growth factor are most representative as they are not only strong polypeptide factors for promoting cell growth, but also important mitogens, which promote the proliferation and differentiation of stem cells into nerve cells through corresponding receptors on the cell surface (Türeyen et al., 2005). However, epidermal growth factor and basic fibroblast growth factor not only are expensive, they also promote excessive cell growth, which potentially increases tumorigenic risks. Hence, epidermal growth factor and basic fibroblast growth factor are infeasible for clinically use as inducers to obtain the target cells and are mainly used in basic laboratory research. However, it would kill two birds with one stone if currently approved drugs could be utilized to induce the differentiation of stem cells into nerve cells.

In recent years, the success of stem cell differentiation induced by traditional Chinese medicine compound preparations and/or monomers has given hope to stem cell researchers (Xu et al., 2013; Wei et al., 2017). A *Ginkgo biloba* extract, EGb761, is becoming one of the focuses of stem cell researchers (Schneider, 2008). It is classified as a western medicine and its clinical application has been accepted worldwide. The main chemical components of EGb761 are flavonoids, terpenoid esters, small amounts of polyphenols, alkaloids, long chain alcohols, ketones, and trace elements (Kleijnen and Knipschild, 1992; Chi et al., 1997; Yuan et al., 2010). Approximately 87% of the components have been identified (Lang et al., 2013), and their approximate proportions and possible functions are shown in **[Table 1](#T1){ref-type="table"}**.

###### 

Main components of EGb761 and their possible functions

  Component                                                                                                                                                                Proportion                                                                                                                                                    Function
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Flavonoids: approximately 38 species, mainly Monoflavones, Flavonols and their glycosides, Biflavones and Latechines, which usually combine with glycosides.             24%                                                                                                                                                           Excellent natural antioxidants that can scavenge free radicals.
  Terpenoids lactone: mainly including diterpenoids such as Ginkgolide A, B, C, M and J, and sesquiterpenoids such as Bilobalide.                                          6% (Ginkgolides 3.1% and Bilobalide 2.9%, Bilobalide may be the metabolic intermediates of Ginkgolides)                                                       The content of Ginkgolides is the key to evaluate EGb761 quality. Ginkgolides have a strong specific inhibitory effect on platelet activating factor (PAF) receptor, of which Ginkgolide B has the highest anti-PAF activity.
  Others: polyisoenenol, fatty acids, hydroxy acids, shikimic acids, amino acids, 6-HKA, ginkgo acids (mainly Ginkgolic Acid, Hydroginkgolic Acid, Bilobo1 and Ginkgol).   Non flavonoid glycosides 20%, carboxylic acids 13%, proanthocyanidins 7%, catechin 2%, macromolecule compounds 4%, inorganic matter 5%, water 3%, other 3%.   Polyisopenyl alcohol is a type of polygene (or dolichol). It is a lipid compound in *Ginkgo biloba* leaves that has cis and trans forms, and plays an important role in maintaining liver function and promoting hematopoiesis. 6-HKA is a broad-spectrum central nervous amino acid antagonist. It acts on N-methyl-D-aspartate to reduce brain hypoxia. Ginkgo acids may be associated with allergy and mutagenesis, therefore are toxic and side effect components of *Ginkgo biloba* extract. Its content should be controlled below 5 μg/g.

Studies have shown that EGb761 can antagonize oxygen free radicals, stabilize cell membranes, promote neurogenesis and synaptic plasticity, and improve the level of brain-derived neurotrophic factors, approximating the environment required during the differentiation of stem cells into nerve cells. This offers the possibility of using EGb761 to induce the differentiation of stem cells and provide cell protection after stem cell transplantation. Against this background, we reviewed world-wide studies of the influence of EGb761 on stem cells, in order to provide a comprehensive reference for the future application of EGb761 in stem cell therapy.

Literature Retrieval {#sec1-2}
====================

We searched the PubMed and Wanfang electronic databases to obtain relevant articles in English and Chinese published up until August 2018 regarding the effects of *Ginkgo biloba* extracts on the nervous system and stem cells using the following retrieval criteria: *Ginkgo biloba* extract, stem cells, induction, differentiation, and nerve. The results were further screened by title and abstract to only present *Ginkgo biloba* extract, neurological diseases, neuropharmacology, and stem cells. Case reports were excluded, but review articles were retained. The articles retrieved are summarized here.

Background to EGb761 {#sec1-3}
====================

EGb761 is extracted from the leaves of the *Ginkgo biloba*, tree, which originated 200 million years ago, and is thus often termed a living fossil. *Ginkgo biloba* is mainly found in China and Japan. The leaves were first used as medicine in the Ming Dynasty of ancient China to treat senile cardiovascular diseases. However, as unprocessed *Ginkgo biloba* leaves contain hydrocyanic acid, which accelerates heart rates, unwelcome side effects occurred (Kumar and Kumar, 2018).

The pharmaceutical development of EGb761 was very active in the 1960s, and the most representative work was promoted by the German company Dr. Willmar Schwabe Pharmaceuticals, who used the leaves of *Ginkgo biloba* sourced from Japan, as raw material. Around the same time, Japanese scientists also tried to develop EGb761 as a drug. However, because natural extracts contain a variety of ingredients, it was difficult to obtain drug approval in Japan. As reported in a special issue of *The Lancet* (Kleijnen and Knipschild, 1992), the German team focused on basic research and clinical trials of EGb761. EGb761 was finally approved as a drug in Germany in 1967, and in France later. In the 1980s, more than ¥20 billion worth of EGb761 sold in Germany, becoming the best-selling drug in the field. In 1991, the German company Dr. Willmar Schwabe Pharmaceuticals produced the standardized *Ginkgo biloba* leaf extract, Ginaton, and patented it. Its quality indexes are: flavonoid glycosides ≥ 24%, terpene lactones ≥ 6%, ginkgolic acids ≤ 5 ppm, and this standard has been adopted in many countries.

Pharmacological Effect of EGB761 on the Nervous System {#sec1-4}
======================================================

The pharmacological action of EGb761 mainly focuses on nervous system function, the anti-oxidation activity of clearing free radicals, anti-platelet aggregation, and improving hemorheology (Zhang et al., 2017b). Research on its function in the nervous system mainly focuses on the protection of the cerebral cortex, hippocampus, substantia nigra, and spinal cord (Defeudis and Drieu, 2000; Maclennan et al., 2002; Ponto and Schultz, 2003). It is widely used in the clinical treatment of nervous system diseases and its curative effect has been confirmed, particularly in cerebrovascular disease and Alzheimer's disease (Chan et al., 2007; Zhang et al., 2013, 2017a). At present, the mechanisms of EGb761's effect on the nervous system mainly include:

Influencing nerve cell apoptosis {#sec2-1}
--------------------------------

Clearing free radicals and anti-oxidation: Oxidative stress is a common cause of neuronal apoptosis. The mechanism of EGb761's free radical clearance and anti-oxidation activity has mostly been studied through oxidative stress-induced dynamic changes in oxidative stress and anti-oxidative stress substances (Pan, 2005) and through free radical induced alteration in gene expression (Xin et al., 2000). At present, it is believed that EGb761 contains flavonoids that can directly scavenge free radicals. Additionally, EGb761 can reduce the formation of oxygen free radicals and the release of superoxide anions by stimulating cytochrome P450 enzyme systems, thus exerting an indirect anti-oxidation effect (Logani et al., 2000).

Stabilizing biofilm and protecting the mitochondria: Mitochondrial damage is an important step in nerve cell apoptosis. In addition to scavenging free radicals and anti-oxidation functioning, EGb761 also protects mitochondria by stabilizing the cell membrane, antagonizing Ca^2+^ overload, regulating enzymes in the respiratory chain, and regulating mitochondrial membrane potential (Ni et al., 1996; Tendi et al., 2002; Chen et al., 2010).

Effect on neurotransmitters {#sec2-2}
---------------------------

Studies have found that EGb761 has an effect on neurotransmitter systems (**[Table 2](#T2){ref-type="table"}**) including the cholinergic systems (Nathan, 2000), monoamine transmitter systems (White et al., 1996; Pardon et al., 2004; Zhang and Cai, 2005), and amino acid neurotransmitters (Chandrasekaran et al., 2003; Wang and Chen, 2005), which is the basis for the increasingly extensive application of EGb761 in neuropsychiatry. Of these systems, EGb761 has the greatest effect on the cholinergic system, which is an important target for the clinical treatment of cognitive disorders such as Alzheimer's disease.

###### 

EGb761 effects on neurotransmission

  References                     Types of neurontransmission     Effects
  ------------------------------ ------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nathan (2000)                  Cholinergic systems             Immediate actions: Upregulation of post-synaptic muscarnic receptors, modulation of pre-synaptic choline uptake and acetylcholine release, reduction of scopolamine-induced amnesia; Indirect effects: modulation of the serotonergic systems.
  White et al. (1996)            Monoamine transmitter systems   Inhibit monoamine oxidase (MAO): Both MAO-A and -B types were inhibited to a similar extent; reduction 5-hydroxyindolacetic acid levels, which is metabolite of serotonin; actions on alpha-2-adrenoceptors.
  Pardon et al. (2004)                                           
  Zhang and Cai (2005)                                           
  Chandrasekaran et al. (2003)   Amino acid neurotransmitters    Against glutamate-induced exitotoxicity by affecting glutamate release
  Wang and Chen (2005)                                           

Effect on synaptic plasticity and nerve regeneration {#sec2-3}
----------------------------------------------------

EGb761's effects on synaptic plasticity mainly relate to the synaptic excitatory activity of neurons in the hippocampus and the induction and formation of long-term potentiation (Smriga et al., 1997), which is another important target for its clinical application in the treatment of cognitive disorders such as Alzheimer's disease. Recently, an increasing number of studies have found that bilobalide, a sesquiterpene in EGb761, can promote nerve regeneration and increase the level of brain derived neurotrophic factors (Tchantchou et al., 2007; Tchantchou and Pncao, 2009). This has become a point of focus for many researchers, and is also the focus of this review.

Others {#sec2-4}
------

EGb761 also has therapeutic effects in cerebrovascular diseases and some neurodegenerative diseases by antagonizing platelet activating factor, regulating the metabolism of arachidic acid, and improving brain circulation (Shi, 2009; Shi et al., 2010).

EGB761 Effect on Stem Cells {#sec1-5}
===========================

As already mentioned, EGb761 was originally found to promote the regeneration of endogenous hippocampal neurons in animals (Osman et al., 2016). Recently, the influence of Ginkgolide B, a bioactive component of EGb761, on stem cells has been well reported. As no clinical grade Ginkgolide B has yet been developed, research on the therapeutic influence of EGb761 on stem cells is beginning to receive more attention.

Effect of EGb761 on neural stem cells {#sec2-5}
-------------------------------------

EGb761's effect on NSCs has mostly been studied through the specific effects of Ginkgolide B on NSCs by Chinese researchers (Zheng et al., 2018). Wang et al. (2007a, b), Huang et al. (2003), and Ding et al. (2004) have studied the effects of Ginkgolide B on isolated NSCs *in vitro*, while Niu et al. (2014) and Wang et al. (2014) focused on its effect on endogenous NSCs in vivo. Each of these studies explored the correlation between Ginkgolide B dosage and the differentiation of NSCs, and suggested that different dose-dependent effects impact on differentiated neurons and gliocytes, which may be associated with dose-dependent gene regulation (Si et al., 2014). It was also found that flavonoids in EGb761 can promote the differentiation of NSCs, but a three-dimensional stem cell-derived neural model is needed to confirm this (Wu et al., 2016a).

There have been few studies on the effects of EGb761 itself on NSCs. The few studies reported in English investigated the effects on endogenous NSCs in rat models of vascular dementia (Wang et al., 2013) and NSCs in the mouse cochlear (Wang and Han, 2015; Wang and Wang, 2016). More studies have been published in Chinese but these have mostly focused on EGb761s effects on endogenous NSCs. The effects on isolated NSCs were better explored by Li et al. (2006, 2010), who also found that, like Ginkgolide B, the induction outcome of EGb761 was dosage dependent and the optimal dosage of EGb761 was needed for the highest yield of nerve cells (Note: this dosage cannot be too high or too low).

Effect of EGb761 on mesenchymal stem cells {#sec2-6}
------------------------------------------

Previous studies have usually focused on the induction of MSCs towards osteogenesis (Gu et al., 2015) and adipogenesis (Wu et al., 2016b) by EGb761. In recent years, scholars began to pay attention to the EGb761-induced differentiation of MSCs into nerve cells. Among them, Li et al. (2013) focused on adipose MSCs, while Su et al. (2007) and Lu et al. (2012) studied bone marrow MSCs, the latter two groups using Ginkgolide B. Whether EGb761 or Ginkgolide B was used, the effect on MSCs in inducing differentiation into nerve cells was time-sensitive, but not dosage-dependent. Additionally, when there was no other neural inducing factor in the induction scheme, EGb761 promoted the differentiation of MSCs into nerve cells rather than into glial cells. The mechanism of this requires further investigation. However, another study of the protective effect of EGb761 on MSCs (Wang et al., 2018) provided another idea for the future application of EGb761 in stem cell therapy, that is, acting as the "guard of MSCs" during MSCs transplantation (Hao et al., 2016).

Other effects {#sec2-7}
-------------

Ginkgolide B can induce NSCs to differentiate into dopaminergic neurons *in vitro* (Tan et al., 2016). Additionally, studies of the effects of EGb761 or Ginkgolide B on embryonic stem cells (Chan, 2006; Yander et al., 2010) and peripheral blood endothelial progenitor cells (Dong et al., 2007) have also brought new ideas for the application of stem cell therapy to nervous system diseases.

Problems and Perspectives {#sec1-6}
=========================

Numerous studies have shown that the interaction of EGb761 with stem cells offers hope for treating nervous system diseases. This is because EGb761 can promote neurogenesis and synaptic plasticity, and raise the level of brain-derived neurotrophic factors, thus replicating the environment required during the differentiation of stem cells into nerve cells. This makes possible the application of EGb761 to induce stem cell differentiation and cell protection after stem cell transplantation (**[Figure 1](#F1){ref-type="fig"}**). Relevant patents have already been applied for, such as by the team of Wen-jie Zhao (patent No. CN101396355A) and Yuan-Shan Zeng (patent No. CN1446907A). Therefore, the use of EGb761 to promote the homing of stem cells and to enhance the ability of neural differentiation in stem cell transplantation is worthy of attention. We are currently exploring this field (a project from NSFC 81501185), but the study of EGb761 and the neural differentiation of stem cells is still in its initial stages. At present, most of the studies of the effects of EGb761 on the induction and transplantation of stem cells are conducted in animals. The regulatory mechanism of the neural differentiation of stem cells is very complicated and EGb761 might have a biphasic effect on the neural differentiation of stem cells (Li et al., 2011).

![Possible effects of EGb761 on nerve repair.](NRR-14-1152-g001){#F1}

While it is worthwhile to further study the possibility of the combined use of EGb761 and stem cell transplantation, as well as its specific mechanisms and targets, because the components of the traditional Chinese medicines are complicated, the potential side effects of EGb761 or its impact on other systems should be of concern. For example, it may cause nervous system effects such as dizziness and headache. However, sometimes it might be better to pay attention to promoting clinical transformation (Freedman and Uccelli, 2012). As Sir Martin Evans, the Nobel Prize winner, said in an interview with Life Times, the current focus of stem cell research is to apply experimental results to practical clinical treatment.

China is rich in *Ginkgo biloba* resources, yielding 70% of the world total of leaves. The use of EGb761 is a merger of eastern and western medicine, but the contribution of the east is often minimized or left out. *Ginkgo biloba* has been used in Chinese Medicine for centuries, however, its research, development, and utilization in China still falls far behind that of developed countries, despite the raw materials of *Ginkgo biloba* leaves used for pharmaceuticals being mainly produced in China. The development and utilization of *Ginkgo biloba* leaves should be accelerated in China, especially when stem cell research is a hot topic, to benefit people worldwide.
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